

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

Claim 1. (Currently Amended) A method for identifying a type of leukemia in a human subject, said method comprising:

obtaining a biological sample from said human subject, said sample comprising at least one CD-surface marker antigen~~antigen-associated with that is present on the cell surface of~~ a type of leukocyte;

contacting said sample with an array of immunoglobulin molecules immobilized to a solid support, having specificity wherein the immunoglobulin molecules are specific for said CD-surface marker antigens, and wherein at least five-seven of the CD-surface marker antigens are selected from the list consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD9, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42, CD42a, CD45, CD45RA, CD45RO, CD52, CD56, CD57, CD60, CD61, CD71, CD79a, CD95, CD103, CD117, CD122, and CD154, glycophorin A, HLA-DR, KOR-SA3544, and FMC7; ~~and, wherein said array comprises said immunoglobulin molecules immobilized to a solid support; and,~~

determining which CD-surface marker antigens have bound to which immobilized immunoglobulin molecules to thereby establish a discriminatory image of antigen expression and which expression a pattern of presence or absence or level of CD-antigens, which pattern is characteristic of a type of leukemia.

Claim 2. (Previously Presented) The method of Claim 1, wherein the immunoglobulin molecules are monoclonal antibodies.

Claims 3. – 6. (Cancelled)

Claim 7. (Currently Amended) The method of Claim 1, wherein at least one of the immunoglobulin molecules in the array is capable of interaction with a CD-cell surface antigen from chronic lymphocytic leukemia (CLL).

Claim 8. (Currently Amended) A method according to claim 1, wherein at least one of the immunoglobulin molecules in the array is capable of interaction with a cell surface ~~CD~~-antigen from hairy cell leukemia (HCL).

Claim 9. (Currently Amended) A method according to claim 1, wherein at least one of the immunoglobulin molecules in the array is capable of interaction with a cell surface ~~CD~~-antigen from chronic myeloid leukemia (CML).

Claim 10. (Currently Amended) A method according to claim 1, wherein at least one of the immunoglobulin molecules in the array is capable of interaction with a cell surface ~~CD~~-antigen from acute myeloid leukemia (AML).

Claim 11. (Currently Amended) A method according to claim 1, wherein at least one of the immunoglobulin molecules in the array is capable of interaction with a cell surface ~~CD~~-antigen from T-cell acute lymphocytic leukemia (ALL).

Claim 12. (Currently Amended) A method according to claim 1, wherein the at least one of the immunoglobulin molecules in the array is capable of interaction with a cell surface ~~CD~~-antigen from acute myelomonocytic leukaemia (AMML).

Claim 13. (Currently Amended) A method according to claim 1, wherein at least one of the immunoglobulin molecules in the array is capable of interaction with a cell surface ~~CD~~-antigen from acute erythrocytic leukemia (AEL).

Claim 14. (Currently Amended) A method according to claim 1, wherein at least one of the immunoglobulin molecules in the array is capable of interaction with a cell surface ~~CD~~-antigen from acute megakaryocytic leukemia (AMegL).

Claim 15. (Currently Amended) A method according to claim 1, wherein at least one of the immunoglobulin molecules in the array is capable of interaction with a cell surface ~~CD~~-antigen from acute monocytic leukemia (AMoL).

Claim 16. (Currently Amended) A method according to claim 1, wherein at least one of the immunoglobulin molecules in the array is capable of interaction with a cell surface ~~CD~~-antigen from non-Hodgkin's lymphoma (NHL).

Claim 17. (Currently Amended) A method according to claim 1, wherein at least one of the immunoglobulin molecules in the array is capable of interaction with a cell surface ~~CD~~-antigen from acute promyelocytic leukemia (APL).

Claim 18. (Previously Presented) The method of Claim 1 wherein the immunoglobulin molecules are polyclonal antibodies.

Claim 19. (Previously Presented) The method of Claim 1 wherein the biological sample is selected from the list consisting of cells, cell debris, cell extracts, tissue fluid, serum, plasma, blood, cerebrospinal fluid, urine, lymphatic fluid, seminal fluid, aspirate, bone marrow aspirate and mucus.

Claim 20. (Previously Presented) The method of Claim 19 wherein the biological sample is blood.

Claim 21. (Previously Presented) The method of Claim 1, wherein the immunoglobulin molecules are antigen binding fragments of immunoglobulin molecules.